Antonio Anzueto - Articles and news items

Landmark TIOSPIRTM trial reinforces importance of SPIRIVA® in both available formulations as the world’s leading maintenance therapy for chronic obstructive pulmonary disease (COPD)

Industry news, News / 9 September 2013 / Boehringer Ingelheim

TIOSPIR™, with over 17,000 COPD patients included and one of the largest international COPD trials ever conducted…

Boehringer Ingelheim logo

SPIRIVA®* celebrates 10 years of ongoing commitment to patients and advancing clinical innovation in COPD

Industry news, News / 3 September 2012 / Boehringer Ingelheim

SPIRIVA® is the most prescribed COPD maintenance treatment worldwide…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+